Connect to other sites within the UBM Medica Network
“Sticky” CML Cells Could Mediate Resistance to Treatment
A subgroup of chronic myeloid leukemia (CML) cells that were “sticky,” or adherent to plastic, showed higher expression levels of BCR-ABL and were more resistant to treatment with the tyrosine kinase inhibitor imatinib.
Test in Development to Monitor CML Patients Halting Nilotinib Treatment
MolecularMD and Novartis are working on a diagnostic test to help determine which chronic myeloid leukemia patients may be candidates to stop taking nilotinib.
First-Line Treatment for Patients With CML in Chronic Phase: Why Imatinib Is an Appropriate Choice
I am very comfortable in using imatinib as initial therapy in most patients who present in chronic phase, with the possible exception of patients with more advanced disease and higher Sokal scores.
First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice
How often do we choose the “second best” treatment as initial therapy for our patients with cancer? The management of chronic myeloid leukemia should be no different.
State of CML Treatments
In this interview, we discuss the current state of therapies available in treating CML patients and the role of newer agents.
EUTOS Score Validated for Predicting Treatment Outcomes With TKI Therapy
A new study validates a simple prognostic score, the EUTOS score, as a useful tool in predicting the therapeutic effects of TKIs for chronic myeloid leukemia.
Ponatinib Receives Marketing Authorization in Europe for CML and Ph+ ALL
ARIAD has received marketing authorization from the European Commission for ponatinib (Iclusig) in chronic myeloid leukemia and acute lymphoblastic leukemia.
Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.
By clicking Accept, you agree to become a member of the UBM Medica Community.